Solid Biosciences LLC Cash Flow Conversion Efficiency
Solid Biosciences LLC cash flow conversion efficiency. Based on the latest financial reports, Solid Biosciences LLC (SLDB) has a cash flow conversion efficiency ratio of -0.141x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-52.59 Million) by net assets ($374.07 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Solid Biosciences LLC (2015–2025)
Cash flow conversion efficiency of Solid Biosciences LLC from 2015 to 2025. This chart illustrates how Solid Biosciences LLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Solid Biosciences LLC for real-time trading data and today's change.
Solid Biosciences LLC Cash Flow Conversion Ratio Explained
Solid Biosciences LLC cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Solid Biosciences LLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Solid Biosciences LLC ranked by their cash flow conversion efficiency. Also see how much is Solid Biosciences LLC worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Wenzhou Hongfeng Electrical Alloy Co Ltd
SHE:300283
|
0.047x |
|
Sunyard System Engineering Co Ltd
SHG:600571
|
-0.078x |
|
Zhejiang Truelove Vogue Co Ltd
SHE:003041
|
0.010x |
|
Tianjin Economic-technological Development Area Co Ltd
SHE:000652
|
0.044x |
|
Reitir fasteignafélag hf
IC:REITIR
|
0.028x |
|
Cognyte Software Ltd
NASDAQ:CGNT
|
-0.021x |
|
Shanghai Smith Adhesive New
SHG:603683
|
0.023x |
|
Henan Hengxing Science & Technology Co Ltd
SHE:002132
|
0.017x |
Annual Cash Flow Conversion Efficiency for Solid Biosciences LLC (2015–2025)
The table below shows the annual cash flow conversion efficiency of Solid Biosciences LLC from 2015 to 2025. Review Solid Biosciences LLC (SLDB) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $180.01 Million | $-156.29 Million | -0.868x | -19.15% |
| 2024-12-31 | $137.25 Million | $-100.01 Million | -0.729x | +2.14% |
| 2023-12-31 | $126.48 Million | $-94.18 Million | -0.745x | -60.86% |
| 2022-12-31 | $211.67 Million | $-97.98 Million | -0.463x | -23.94% |
| 2021-12-31 | $208.21 Million | $-77.76 Million | -0.373x | +12.84% |
| 2020-12-31 | $132.09 Million | $-56.60 Million | -0.429x | +63.00% |
| 2019-12-31 | $80.05 Million | $-92.71 Million | -1.158x | -106.55% |
| 2018-12-31 | $125.18 Million | $-70.20 Million | -0.561x | -176.88% |
| 2017-12-31 | $-59.26 Million | $-43.22 Million | 0.729x | +37.35% |
| 2016-12-31 | $-37.89 Million | $-20.12 Million | 0.531x | +151.70% |
| 2015-12-31 | $-19.93 Million | $-4.20 Million | 0.211x | -- |
About Solid Biosciences LLC
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachyca… Read more